+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 287 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5934424
Description Jump to:
The global mycobacterium tuberculosis treatment market, valued at US$2.15 billion in 2024, is poised for steady growth, according to a comprehensive study by the publisher. The market is expected to approximately US$2.4 billion by the end of 2031.

Challenges Posed by Tuberculosis

Tuberculosis remains a pressing global health issue, with 1.6 million deaths reported worldwide in 2021, making it the second leading infectious killer globally, following COVID-19 and HIV/AIDS. There were approximately 10.6 million reported cases of tuberculosis in 2021, affecting people of all ages.

The COVID-19 pandemic had a significant impact on tuberculosis diagnosis and treatment in 2020, leading to a 21% decline in TB treatment compared to 2019. Restrictions on movement, resource reallocation, and insufficient equipment and capacity hampered the provision of tuberculosis services.

Despite these challenges, the market for mycobacterium tuberculosis treatment is set to exhibit growth over the coming years. Government initiatives and National Strategic Plans aimed at eradicating tuberculosis by 2025 are expected to fuel steady growth in the market.

Growth Opportunities for Mycobacterium Tuberculosis Drug Manufacturers

  • Rising Incidence of Multi-Drug Resistant Tuberculosis (MDR-TB): The prevalence of MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) is expected to increase in developing nations. Global initiatives like the WHO's Directly Observed Therapy (DOT) program are addressing the challenge of antimicrobial drug resistance in mycobacterium TB strains.
  • Advancements in Novel Therapeutics and International Funding: Ongoing advancements in technology and the development of novel therapeutics are anticipated to shorten tuberculosis treatment duration and reduce its occurrence. International donor funding, including contributions to the Global Fund, remains crucial for low- and middle-income countries to combat tuberculosis effectively.

Market Progress and Competition

The availability of generic alternatives to tuberculosis medications has led to a wide range of low-cost prescription options. As branded pharmaceuticals lose patent protection, pharmaceutical companies face competition from generic drugs. This competition is expected to increase as more drugs enter the market, impacting manufacturers of original products.

Country-wise Insights

United States: The U.S. is a significant player in the global Mycobacterium Tuberculosis Treatment Market. The incidence of tuberculosis has been on the rise among both U.S.-born and non-U.S.-born individuals, contributing to market growth. The U.S. government is a major contributor to international funding for TB programs, which further supports market development.

China: China is emerging as a prominent market for Mycobacterium Tuberculosis drug suppliers in East Asia. The country has a high burden of latent tuberculosis infection (LTBI), with millions of people at risk for active TB illness. The Chinese government has initiated programs like the Healthy China Initiative 2024–2031, including Tuberculosis Control Action, which is expected to drive market growth.

India: India has a significant share of the South Asian market for Mycobacterium Tuberculosis treatment. The country has a high prevalence of tuberculosis and drug-resistant tuberculosis (MDR-TB). The incidence of tuberculosis has been increasing, and there are ongoing digital initiatives, such as #BeTheChangeForTB, supported by government and international agencies, to combat the disease.

Competitive Analysis

Key players in the mycobacterium tuberculosis treatment industry are actively engaged in activities such as new product launches, acquisitions, collaborations, and expansion to advance and develop new products and therapies.

Key Companies Profiled

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Key Segments of Mycobacterium Tuberculosis Treatment Industry Research

By Disease Type:

  • Latent TB
  • Active TB

By Treatment Type:

  • First-Line of Drugs
  • Second-Line of Drugs

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Institutional and Retail Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Mycobacterium Tuberculosis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
3.1. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Latent TB
3.1.1.2. Active TB
3.2. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. First-Line of Drugs
3.2.1.2. Second-Line of Drugs
3.3. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Intravenous
3.3.1.3. Intramuscular
3.4. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Online Pharmacies
3.4.1.3. Retail Pharmacies
3.4.1.4. Institutional and Retail Sales
3.5. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
4.1. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Latent TB
4.1.1.2. Active TB
4.2. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. First-Line of Drugs
4.2.1.2. Second-Line of Drugs
4.3. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Intravenous
4.3.1.3. Intramuscular
4.4. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Online Pharmacies
4.4.1.3. Retail Pharmacies
4.4.1.4. Institutional and Retail Sales
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.5.1.2. U.S. Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.5.1.3. U.S. Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.5.1.4. U.S. Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1.5. Canada Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.5.1.6. Canada Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.5.1.7. Canada Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.5.1.8. Canada Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
5.1. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Latent TB
5.1.1.2. Active TB
5.2. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. First-Line of Drugs
5.2.1.2. Second-Line of Drugs
5.3. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Intravenous
5.3.1.3. Intramuscular
5.4. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Online Pharmacies
5.4.1.3. Retail Pharmacies
5.4.1.4. Institutional and Retail Sales
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.2. Germany Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.3. Germany Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.4. Germany Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.5. U.K. Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.6. U.K. Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.7. U.K. Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.8. U.K. Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.9. France Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.10. France Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.11. France Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.12. France Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.13. Italy Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.14. Italy Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.15. Italy Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.16. Italy Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.17. Turkey Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.18. Turkey Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.19. Turkey Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.20. Turkey Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.21. Russia Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.22. Russia Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.23. Russia Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.24. Russia Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.25. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.5.1.26. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.5.1.27. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.28. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Latent TB
6.1.1.2. Active TB
6.2. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. First-Line of Drugs
6.2.1.2. Second-Line of Drugs
6.3. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Intravenous
6.3.1.3. Intramuscular
6.4. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Online Pharmacies
6.4.1.3. Retail Pharmacies
6.4.1.4. Institutional and Retail Sales
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.2. China Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.3. China Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.4. China Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.5. Japan Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.6. Japan Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.7. Japan Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.8. Japan Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.9. South Korea Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.10. South Korea Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.11. South Korea Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.12. South Korea Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.13. India Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.14. India Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.15. India Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.16. India Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.17. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.18. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.19. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.20. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
7.1. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Latent TB
7.1.1.2. Active TB
7.2. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
7.2.1.1. First-Line of Drugs
7.2.1.2. Second-Line of Drugs
7.3. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Intravenous
7.3.1.3. Intramuscular
7.4. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Online Pharmacies
7.4.1.3. Retail Pharmacies
7.4.1.4. Institutional and Retail Sales
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.2. Brazil Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.3. Brazil Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.4. Brazil Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.5. Mexico Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.6. Mexico Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.7. Mexico Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.8. Mexico Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.9. Argentina Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.10. Argentina Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.11. Argentina Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.12. Argentina Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.13. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.5.1.14. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.5.1.15. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.16. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Latent TB
8.1.1.2. Active TB
8.2. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. First-Line of Drugs
8.2.1.2. Second-Line of Drugs
8.3. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Intravenous
8.3.1.3. Intramuscular
8.4. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Online Pharmacies
8.4.1.3. Retail Pharmacies
8.4.1.4. Institutional and Retail Sales
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.2. GCC Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.3. GCC Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.4. GCC Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.5. South Africa Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.6. South Africa Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.7. South Africa Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.8. South Africa Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.9. Egypt Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.10. Egypt Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.11. Egypt Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.12. Egypt Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.13. Nigeria Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.14. Nigeria Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.15. Nigeria Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.16. Nigeria Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Application Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. AstraZeneca
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Johnson & Johnson Private Limited
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Eli Lilly and Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. F. Hoffmann-La Roche Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Mylan N.V.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Teva Pharmaceutical Industries Ltd.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Vostra Gmbh
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Sanofi
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Novartis AG
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Sun Pharmaceutical Industries Ltd.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Aurobindo Pharma
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Lupin
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Allergan
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. Merck & Co., Inc.
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Vostra Gmbh
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 - Product Image

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

  • Report
  • Global
From
Tuberculosis Diagnostics Global Market Report 2024 - Product Image

Tuberculosis Diagnostics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Tuberculosis Diagnosis and Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Tuberculosis Diagnosis and Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 117 Pages
  • Global
From
Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
2024-2028 Global Tuberculosis (TB) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Image

2024-2028 Global Tuberculosis (TB) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.